In recent years, the number of approved and investigational agents that can be safely
administered for the treatment of lymphoma patients for a prolonged period of time has …

Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally.
The landscape of systemic therapy has recently changed, with six additional systemic …

Background Despite some successes with checkpoint inhibitors for treating cancer, most
patients remain refractory to treatment, possibly due to the inhibitory nature of the tumor …

Immunotherapy is innovating clinical cancer management. Nevertheless, only a small
fraction of patient's benefit from current immunotherapies. To improve clinical management …

Peripheral T-cell lymphomas (PTCL), a heterogeneous group of mature aggressive non-
Hodgkin's lymphomas, carry a worse prognosis for most subtypes when compared with their …

Radioembolization gains continuous traction as a primarily palliative radiation treatment for
hepatic tumours. A form of nuclear medicine therapy, Yttrium-90 containing microspheres …

This commentary is a call to action for a concerted commitment and effort to transform
clinical trials and enable people with cancer to participate in clinical trials closer to home …

Abstract Purpose: The phase III CELESTIAL study demonstrated improved overall survival
(OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with …

Osteosarcomas (OS), especially those with metastatic or unresectable disease, have limited
treatment options. The greatest advancement in treatments occurred in the 1980s when …

Transarterial radioembolization (TARE), also called radioembolization or selective internal
radiation therapy, is an interventional radiology technique used to treat primary liver tumors …